---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-006852"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:27:06.096071+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Xilio reports Q1 net loss $13.3M, cash $89.1M; AbbVie deal provides $52M upfront

## Summary
- Net loss $13.3M for Q1 2025, vs $17.2M Q1 2024.
- Cash $89.1M as of Mar 31, 2025, up from $55.3M at Dec 31, 2024, driven by $52M AbbVie upfront.
- R&D expenses $8.3M (down from $10.4M); G&A $8.5M (up from $6.1M) year-over-year.
- Updated Phase 2 data for vilastobart + atezolizumab in MSS CRC to be presented at ASCO 2025 (abstract 3553).
- First development candidates for masked T cell engagers (PSMA, CLDN18.2, STEAP1) expected H2 2025–H1 2026.

## SEC filing metadata
- accession: 0001558370-25-006852
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000155837025006852/0001558370-25-006852-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000155837025006852/xlo-20250508x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-006852
- JSON: https://secwatch.observer/filing/0001558370-25-006852.json
- Plain text: https://secwatch.observer/filing/0001558370-25-006852.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.